Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease

Figure 1 Frequency of liver fibrosis risk in patients with metabolic-dysfunction-associated fatty liver disease according to fibrosis-4, nonalcoholic fatty liver disease score and aspartate aminotransferase-to-platelet ratio index, n (%). APRI: Aspartate aminotransferase-to-platelet ratio index; NAFLD: Nonalcoholic fatty liver disease; FIB-4: Fibrosis-4.

Figure 2 Distribution of cardiovascular risk. A: Distribution of cardiovascular risk (CVR) according to the Framingham system in patients with metabolic-dysfunction-associated fatty liver disease and risk of liver fibrosis according to fibrosis-4 (FIB-4) (n = 125); B: Distribution of CVR estimated by the Framingham system in patients with metabolic-dysfunction-associated fatty liver disease according to hepatic fibrosis estimation with transient elastography (n = 69), n (%). Degrees of fibrosis by Kpa according to METAVIR: Absent: F0; Mild–moderate: F1 and F2; Advanced: F3 and F4. CVR: Cardiovascular risk; FIB-4: Fibrosis-4.